Novo Nordisk Reports P-III Trial (STEP-HFpEF) Results of Semaglutide for Heart Failure with Preserved Ejection Fraction and Obesity
Shots:
- The P-III trial evaluating semaglutide (2.4mg, qw) vs PBO in 529 patients, showed a large reduction in HF-related symptoms, physical limitations, and improvements in exercise function resulted in greater weight loss in adults with HFpEF & obesity, a large improvement in patient-reported KCCQ-CSS
- Mean change in the KCCQ-CSS at 52wks. (16.6 vs 8.7 points); body weight reduction (13.3% vs 2.6%); an increase in 6MWD of 21.5 vs 1.2 meters at 52wks. The safety profile was consistent with prior studies with fewer serious AEs
- The results were presented at the ESC Congress in Amsterdam, Netherlands & published in the NEJM. The (STEP HFpEF-DM) study is expected to be completed in Q4’23 while the company plans to file for approval of the Wegovy label update in the US & EU in H1’24
Ref: Novo Nordisk | Image: Novo Nordisk
Related news:- Novo Nordisk Reports P-IIIa Trial (OASIS 1) Results of Semaglutide for the Treatment of Obesity or Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
